New Zealand markets close in 4 hours 56 minutes
  • NZX 50

    11,611.81
    -42.75 (-0.37%)
     
  • NZD/USD

    0.6369
    +0.0072 (+1.14%)
     
  • NZD/EUR

    0.6050
    +0.0007 (+0.12%)
     
  • ALL ORDS

    7,554.00
    +73.30 (+0.98%)
     
  • ASX 200

    7,354.40
    +70.20 (+0.96%)
     
  • OIL

    81.41
    +0.19 (+0.23%)
     
  • GOLD

    1,817.40
    +2.20 (+0.12%)
     
  • NASDAQ

    12,041.89
    +11.83 (+0.10%)
     
  • FTSE

    7,558.49
    -14.56 (-0.19%)
     
  • Dow Jones

    34,395.01
    -194.76 (-0.56%)
     
  • DAX

    14,490.30
    +93.26 (+0.65%)
     
  • Hang Seng

    18,736.44
    +139.21 (+0.75%)
     
  • NIKKEI 225

    28,226.08
    +257.09 (+0.92%)
     
  • NZD/JPY

    86.1530
    -0.7340 (-0.84%)
     

Vaccine Adjuvants Global Market Report 2022: Government Initiatives Promoting Vaccination Bolsters Sector

Company Logo
Company Logo

Global Vaccine Adjuvants Market

Global Vaccine Adjuvants Market
Global Vaccine Adjuvants Market

Dublin, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The "Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global vaccine adjuvants market size reached US$ 773.6 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,617.3 Million by 2027, exhibiting a CAGR of 13.08% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Vaccine Adjuvants Market Trends:

The global vaccine adjuvants market is primarily driven by the rising prevalence of allergies and infectious diseases, including cancer, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV) and tuberculosis. The need for advanced treatment options for existing and emerging fatal diseases has resulted in the development of vaccines that have long-lasting effects on immunization. For instance, key manufacturers have developed new adjuvants such as AS01, ISCOM & ISCOMMATRIX, and AS02, which are under clinical trials.

Besides this, governments of various countries are taking initiatives for immunization and advancements in adjuvants for human use. They are also focusing on improving healthcare infrastructure and increasing investments for research and development (R&D) of new therapeutics. For example, market players are investing in the development of novel vaccine adjuvants as a potential solution against diseases caused by challenging pathogens, such as malaria and herpes, as well as for vulnerable populations that respond poorly to traditional vaccines, including older adults, neonates, and individuals with compromised immunity and comorbidities.

Moreover, with the spread of the coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, there has been an increasing demand for effective and safe vaccine adjuvants. These factors are expected to provide a positive outlook for the market in the upcoming years.

Key Market Segmentation

Breakup by Product Type:

  • Adjuvant Emulsions

  • Pathogen Components

  • Particulate Adjuvants

  • Combination Adjuvants

  • Others

Breakup by Route of Administration:

  • Oral

  • Intramuscular

  • Intranasal

  • Subcutaneous

  • Intradermal

  • Others

Breakup by Diseases:

  • Cancer

  • Infectious Diseases

  • Others

Breakup by Application:

  • Research

  • Commercial

Breakup by Region:

  • North America

  • United States

  • Canada

  • Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Indonesia

  • Others

  • Europe

  • Germany

  • France

  • United Kingdom

  • Italy

  • Spain

  • Russia

  • Others

  • Latin America

  • Brazil

  • Mexico

  • Others

  • Middle East and Africa

Key Questions Answered in This Report:

  • How has the global vaccine adjuvants market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global vaccine adjuvants market?

  • What are the key regional markets?

  • What is the breakup of the market based on the product type?

  • What is the breakup of the market based on the route of administration?

  • What is the breakup of the market based on the diseases?

  • What is the breakup of the market based on the application?

  • What are the various stages in the value chain of the industry?

  • What are the key driving factors and challenges in the industry?

  • What is the structure of the global vaccine adjuvants market and who are the key players?

  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Vaccine Adjuvants Market

6 Market Breakup by Product Type

7 Market Breakup by Route of Administration

8 Market Breakup by Diseases

9 Market Breakup by Application

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

Companies Mentioned

  • Adjuvance Tecchnologies Inc.

  • Adjuvatis

  • Agenus Inc.

  • Brenntag SE

  • Chemtrade Logistics Inc.

  • CSL Limited

  • Croda International Plc

  • Invivogen

  • Novavax Inc.

  • OZ Biosciences

  • Virometix AG.

For more information about this report visit https://www.researchandmarkets.com/r/bw4hj6

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900